A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors
Latest Information Update: 05 Sep 2022
At a glance
- Drugs ET 0038 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms FIRST
- Sponsors Eternal Technologies Group
- 05 Sep 2022 New source identified and integrated ClinicalTrials.gov: (US National Institutes of Health: NCT05525559).
- 30 Aug 2022 Status changed from planning to not yet recruiting.
- 09 Sep 2021 New trial record